0 56 eps expected for nabriva therapeutics plc nbrv


$-0.56 EPS Expected for Nabriva Therapeutics plc (NBRV)


February 18, 2018 – By Stephen Andrade

Analysts expect Nabriva Therapeutics plc (NASDAQ:NBRV) to report $-0.56 EPS on March, 23.They anticipate $0.13 EPS change or 18.84 % from last quarter’s $-0.69 EPS. After having $-0.66 EPS previously, Nabriva Therapeutics plc’s analysts see -15.15 % EPS growth. The stock decreased 3.85% or $0.22 during the last trading session, reaching $5.5. About 164,560 shares traded. Nabriva Therapeutics plc (NASDAQ:NBRV) has risen 15.31% since February 18, 2017 and is uptrending. It has underperformed by 1.39% the S&P500.



Nabriva Therapeutics plc (NASDAQ:NBRV) Ratings Coverage

Among 5 analysts covering Nabriva Therapeutics (NASDAQ:NBRV), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nabriva Therapeutics had 8 analyst reports since October 12, 2015 according to SRatingsIntel. The rating was initiated by Needham on Monday, October 12 with “Buy”. The stock has “Outperform” rating by RBC Capital Markets on Tuesday, October 13. The firm has “Outperform” rating given on Tuesday, October 13 by Wedbush. The stock of Nabriva Therapeutics plc (NASDAQ:NBRV) earned “Outperform” rating by Wedbush on Wednesday, February 1. Gabelli initiated the stock with “Buy” rating in Wednesday, January 27 report. The firm has “Outperform” rating given on Tuesday, October 13 by Leerink Swann. The stock of Nabriva Therapeutics plc (NASDAQ:NBRV) earned “Outperform” rating by RBC Capital Markets on Thursday, November 12. The rating was reinitiated by Leerink Swann on Thursday, October 27 with “Outperform”.

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company has market cap of $201.80 million. The firm focuses on the pleuromutilin class of antibiotics. It currently has negative earnings. The Company’s lead product candidate is lefamulin, which has completed a Phase II clinical trial for acute bacterial skin and skin structure infections.

More notable recent Nabriva Therapeutics plc (NASDAQ:NBRV) news were published by: Globenewswire.com which released: “Nabriva Therapeutics plc Successfully Concludes Tender Offer for Outstanding …” on June 26, 2017, also Globenewswire.com with their article: “Nabriva Commences Previously Announced Tender Offer Related to the Proposed …” published on May 23, 2017, Globenewswire.com published: “Nabriva Announces the Proposed Redomicile of its Holding Company from Austria …” on April 17, 2017. More interesting news about Nabriva Therapeutics plc (NASDAQ:NBRV) were released by: Marketwatch.com and their article: “Nabriva Therapeutics PLC” published on December 11, 2016 as well as Globenewswire.com‘s news article titled: “Nabriva Therapeutics Announces Proposed Public Offering of Ordinary Shares” with publication date: September 18, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Back To Top